Inicio>>Lipids>> P450>>Dihydromethysticin ((+)-Dihydromethysticin)

Dihydromethysticin ((+)-Dihydromethysticin) (Synonyms: NSC 112159)

Catalog No.GC30479

Dihydromethysticin ((+)-Dihydromethysticin) es una de las seis principales kavalactonas que se encuentran en la planta de kava; tiene marcada actividad en la inducciÓn de CYP3A23.

Products are for research use only. Not for human use. We do not sell to patients.

Dihydromethysticin ((+)-Dihydromethysticin) Chemical Structure

Cas No.: 19902-91-1

Tamaño Precio Disponibilidad Cantidad
1mg
70,00 $
Disponible
5mg
175,00 $
Disponible
10mg
294,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dihydromethysticin is one of the six major kavalactones found in the kava plant; has marked activity on the induction of CYP3A23.

[1]. Ma Y, et al. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos. 2004 Nov;32(11):1317-24. [2]. Walden J, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):697-706. [3]. Sarris J, et al. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011 Jan;45(1):27-35.

Reseñas

Review for Dihydromethysticin ((+)-Dihydromethysticin)

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dihydromethysticin ((+)-Dihydromethysticin)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.